Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity.
Ligufalimab binds to human CD47 antigen with an EC50 value of 0.078 nM, KD value of 0.152 nM[1].Ligufalimab (0-3000 nM) does not induce RBC hemagglutination[1].Ligufalimab (0.1, 1, 10 µg/mL) induces phagocytosis of Raji, Jurkat and Ramos cells in a dose-dependent manner[1].
Ligufalimab (0.1, 1 mg/kg for Raji xenograft, 0.2 mg/kg for MDA-MB-231 xenograft model) inhibits tumor growth in mice[1].
References:
[1]. Qu T, et al. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. J Immunother Cancer. 2022 Nov;10(11):e005517.